Cochrane · systematic review · CD013225
Treatments for seizures in catamenial (menstrual‐related) epilepsy
Maguire, MJ, Nevitt, SJ · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
8
No studies
4
Included studies
NR
No studies 4 · 33.3%Ungraded 0 · 0%Very low 3 · 25%Low 2 · 16.7%Moderate 3 · 25%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyNorethisterone compared to placebo for seizures in catamenial epilepsy
Population: women with seizures due to catamenial epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure freedom Norethisterone vs placebo | no estimate extracted | NR | No studies |
Responder rate Norethisterone vs placebo | no estimate extracted | NR | No studies |
Change in seizure frequency Norethisterone vs placebo | no estimate extracted | 24 participants | Very low Downgraded: risk of bias, imprecision |
Number of withdrawals from the study Norethisterone vs placebo | no estimate extracted | 24 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Norethisterone vs placebo | no estimate extracted | 15 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life Norethisterone vs placebo | no estimate extracted | NR | No studies |
Progesterone compared to placebo for seizures in catamenial epilepsy
Population: women with seizures due to catamenial epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure freedom: all seizures Progesterone vs placebo | RR 4.03 [0.21, 76.21] | 1 study · 130 participants | Low Downgraded: risk of bias, imprecision |
Responder rate: 50% or greater reduction in all seizures Progesterone vs placebo | RR 1.14 [0.56, 2.32] | 1 study · 130 participants | Moderate Downgraded: risk of bias, imprecision |
Change in seizure frequency Progesterone vs placebo | no estimate extracted | 2 studies · 166 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Number of withdrawals from the study: for any reason Progesterone vs placebo | RR 1.56 [0.81, 3] | 2 studies · 168 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events: any adverse event Progesterone vs placebo | RR 0.85 [0.59, 1.24] | 1 study · 130 participants | Moderate Downgraded: risk of bias, imprecision |
Quality of life Progesterone vs placebo | no estimate extracted | NR | No studies |
Norethisterone compared to placebo for perimenstrual seizures in catamenial epilepsy
Population: women with perimenstrual seizures due to catamenial epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure freedom Norethisterone vs placebo | no estimate extracted | NR | No studies |
Responder rate Norethisterone vs placebo | no estimate extracted | NR | No studies |
Change in seizure frequency Norethisterone vs placebo | no estimate extracted | 24 participants | Very low Downgraded: risk of bias, imprecision |
Number of withdrawals from the study Norethisterone vs placebo | no estimate extracted | 24 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Norethisterone vs placebo | no estimate extracted | 15 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life Norethisterone vs placebo | no estimate extracted | NR | No studies |
Progesterone compared to placebo for perimenstrual seizures in catamenial epilepsy
Population: women with perimenstrual seizures due to catamenial epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure freedom: all seizures Progesterone vs placebo | RR 4.03 [0.21, 76.21] | 1 study · 130 participants | Low Downgraded: risk of bias, imprecision |
Responder rate: 50% or greater reduction in all seizures Progesterone vs placebo | RR 1.14 [0.56, 2.32] | 1 study · 130 participants | Moderate Downgraded: risk of bias, imprecision |
Change in seizure frequency Progesterone vs placebo | no estimate extracted | 2 studies · 166 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Number of withdrawals from the study: due to any reason Progesterone vs placebo | RR 1.56 [0.81, 3] | 2 studies · 168 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events: any adverse event Progesterone vs placebo | RR 0.85 [0.59, 1.24] | 1 study · 130 participants | Moderate Downgraded: risk of bias, imprecision |
Quality of life Progesterone vs placebo | no estimate extracted | NR | No studies |